Literature DB >> 24051749

Viability and virulence of pneumolysin, pneumococcal surface protein A, and pneumolysin/pneumococcal surface protein A mutants in the ear.

Patricia A Schachern1, Vladimir Tsuprun, Sarah Goetz, Sebahattin Cureoglu, Steven K Juhn, David E Briles, Michael M Paparella, Patricia Ferrieri.   

Abstract

IMPORTANCE: Understanding how pneumococcal proteins affect the pathology of the middle ear and inner ear is important for the development of new approaches to prevent otitis media and its complications.
OBJECTIVES: To determine the viability and virulence of Streptococcus pneumoniae mutants deficient in pneumolysin (Ply-) and pneumococcal surface protein A (PspA-) in the chinchilla middle ear.
DESIGN: Bullae of chinchillas were inoculated bilaterally with wild-type (Wt), Ply-, PspA-, and Ply-/PspA- strains. Bacterial colony-forming units (CFUs) in middle ear effusions were counted at 48 hours. The CFUs of the PspA- group were also counted at 6 to 36 hours after inoculation. Temporal bone histopathological results were compared. SETTING AND PARTICIPANTS: Twenty-seven chinchillas in an academic research laboratory. EXPOSURE: Chinchilla middle ears were inoculated with S pneumoniae to produce sufficient volumes of effusions and noticeable histopathological changes in the ears. MAIN OUTCOMES AND MEASURES: The CFU counts in the middle ear effusions and histopathological changes were compared to determine the effect of pneumococcal protein mutations on chinchilla ears.
RESULTS: At 48 hours, CFUs in middle ears were increased for the Wt and Ply-/PspA- strains, but Ply- remained near inoculum level. No bacteria were detected in the PspA- group. The CFUs of PspA- decreased over time to a low level at 30 to 36 hours. In vitro, PspA- in Todd-Hewitt broth showed an increase in bacterial growth of 2 logs at 43 hours, indicating PspA- susceptibility to host defenses in vivo. The PspA- and Ply- groups had fewer pathologic findings than the Wt or Ply-/PspA- groups. Histopathological analysis showed significant differences in the number of bacteria in the scala tympani in the Wt group compared with the Ply-, PspA-, and Ply-/PspA- groups. The PspA- strain was the least virulent. CONCLUSIONS AND RELEVANCE: The PspA- mutant was much less viable and less virulent in the ear than the Wt, Ply-, and Ply-/PspA- strains. There was no significant attenuation in the viability and virulence of the Ply-/PspA- mutant compared with the Wt or single mutants. The viability and virulence of pneumococcal mutants seemed to be protein and organ specific.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24051749      PMCID: PMC4037925          DOI: 10.1001/jamaoto.2013.4104

Source DB:  PubMed          Journal:  JAMA Otolaryngol Head Neck Surg        ISSN: 2168-6181            Impact factor:   6.223


  27 in total

1.  STUDIES ON THE CHEMICAL NATURE OF THE SUBSTANCE INDUCING TRANSFORMATION OF PNEUMOCOCCAL TYPES : INDUCTION OF TRANSFORMATION BY A DESOXYRIBONUCLEIC ACID FRACTION ISOLATED FROM PNEUMOCOCCUS TYPE III.

Authors:  O T Avery; C M Macleod; M McCarty
Journal:  J Exp Med       Date:  1944-02-01       Impact factor: 14.307

2.  Truncated forms of PspA that are secreted from Streptococcus pneumoniae and their use in functional studies and cloning of the pspA gene.

Authors:  J Yother; G L Handsome; D E Briles
Journal:  J Bacteriol       Date:  1992-01       Impact factor: 3.490

3.  Reduced virulence of a defined pneumolysin-negative mutant of Streptococcus pneumoniae.

Authors:  A M Berry; J Yother; D E Briles; D Hansman; J C Paton
Journal:  Infect Immun       Date:  1989-07       Impact factor: 3.441

Review 4.  The potential for using protein vaccines to protect against otitis media caused by Streptococcus pneumoniae.

Authors:  D E Briles; S K Hollingshead; G S Nabors; J C Paton; A Brooks-Walter
Journal:  Vaccine       Date:  2000-12-08       Impact factor: 3.641

5.  Activation of human complement by the pneumococcal toxin pneumolysin.

Authors:  J C Paton; B Rowan-Kelly; A Ferrante
Journal:  Infect Immun       Date:  1984-03       Impact factor: 3.441

6.  Additive inhibition of complement deposition by pneumolysin and PspA facilitates Streptococcus pneumoniae septicemia.

Authors:  Jose Yuste; Marina Botto; James C Paton; David W Holden; Jeremy S Brown
Journal:  J Immunol       Date:  2005-08-01       Impact factor: 5.422

Review 7.  What can children gain from pneumococcal conjugate vaccines?

Authors:  Heikki Peltola; Robert Booy; Heinz-Josef Schmitt
Journal:  Eur J Pediatr       Date:  2004-06-10       Impact factor: 3.183

8.  Variation in the molecular weight of PspA (pneumococcal surface protein A) among Streptococcus pneumoniae.

Authors:  W D Waltman; L S McDaniel; B M Gray; D E Briles
Journal:  Microb Pathog       Date:  1990-01       Impact factor: 3.738

9.  Interaction of pneumolysin-sufficient and -deficient isogenic variants of Streptococcus pneumoniae with human respiratory mucosa.

Authors:  C F Rayner; A D Jackson; A Rutman; A Dewar; T J Mitchell; P W Andrew; P J Cole; R Wilson
Journal:  Infect Immun       Date:  1995-02       Impact factor: 3.441

10.  Serotypes of Streptococcus pneumoniae causing disease.

Authors:  B M Gray; G M Converse; H C Dillon
Journal:  J Infect Dis       Date:  1979-12       Impact factor: 5.226

View more
  6 in total

1.  Prevalence of PspA families and pilus islets among Streptococcus pneumoniae colonizing children before and after universal use of pneumococcal conjugate vaccines in Brazil.

Authors:  Patricia Alice Knupp-Pereira; Nayara Torres Cardoso Marques; Lúcia Martins Teixeira; Helvécio Cardoso Corrêa Póvoa; Felipe Piedade Gonçalves Neves
Journal:  Braz J Microbiol       Date:  2019-12-04       Impact factor: 2.476

Review 2.  Panel 4: Report of the Microbiology Panel.

Authors:  Stephen J Barenkamp; Tasnee Chonmaitree; Anders P Hakansson; Terho Heikkinen; Samantha King; Johanna Nokso-Koivisto; Laura A Novotny; Janak A Patel; Melinda Pettigrew; W Edward Swords
Journal:  Otolaryngol Head Neck Surg       Date:  2017-04       Impact factor: 3.497

3.  Synchrony in serum antibody response to conserved proteins of Streptococcus pneumoniae in young children.

Authors:  Dabin Ren; Anthony L Almudevar; Michael E Pichichero
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

4.  Pneumococcal PspA and PspC proteins: potential vaccine candidates for experimental otitis media.

Authors:  Patricia A Schachern; Vladimir Tsuprun; Patricia Ferrieri; David E Briles; Sarah Goetz; Sebahattin Cureoglu; Michael M Paparella; Steven Juhn
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2014-06-24       Impact factor: 1.675

Review 5.  The Yin and Yang of Pneumolysin During Pneumococcal Infection.

Authors:  Joana M Pereira; Shuying Xu; John M Leong; Sandra Sousa
Journal:  Front Immunol       Date:  2022-04-22       Impact factor: 8.786

Review 6.  Pneumolysin: Pathogenesis and Therapeutic Target.

Authors:  Andrew T Nishimoto; Jason W Rosch; Elaine I Tuomanen
Journal:  Front Microbiol       Date:  2020-07-02       Impact factor: 5.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.